U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123415) titled 'A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors' on July 29.
Brief Summary: This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects with advanced solid tumors.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Cancer
Advanced Solid Tumor (Phase 1)
Intervention:
DRUG: APX-343A
Oral administration twice daily
DRUG: Pembrolizumab
intravenous [IV]
Recruitm...